Current Research Studies

AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

AALL1732

What is the goal of the study?

The goal of this study is to determine, in a randomized manner, if the addition of 2 blocks of inotuzumab ozogamicin to modified Berlin-Frankfurt-Münster (mBFM) chemotherapy will improve 5-year disease-free survival (DFS) in children and young adults with High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).

Who can participate in the study?

This study may be a good fit for children and young adults who: Are between 1 and 24 years old Patients with B-ALL meet one of the follwing white blood count (WBC) criteria: -Age 1 - 9.99 years: WBC >= 50,000/uL -Age 10 - 24.99 years: Any WBC -Age 1 - 9.99 years: WBC < 50,000/UL with >Testicular leukemia >CNS lukemia (CNS3) >Steriod pretreatment Are newly diagnosed with B-ALL or MPAL (by WHO2016 criteria) with > 25% blasts on a bone marrow (BM) aspirate

Study Team: